MULTIBANK-GROUP
MultiBank Group, a premier forex broker, has proudly received the prestigious accolade of "Best Gold Broker 2024" from FX Empire, a globally acclaimed financial news portal known for its accurate forecasts, comprehensive market insights, detailed broker evaluations, and up-to-the-minute news coverage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507590160/en/
MultiBank Group Honored as Best Gold Broker of 2024 by FX Empire (Graphic: Business Wire)
Established in 2005 in California, USA, MultiBank Group has amassed an impressive collection of over 50 awards. Recognized worldwide as a top-tier broker, MultiBank Group offers a diverse portfolio of more than 20,000 instruments across six asset classes, including forex, metals, indices, shares, cryptocurrencies, and stocks.
This recognition from FX Empire underscores the exceptional quality of service provided by MultiBank Group to its clientele, who rely on the broker for gold trading—an asset that has seen significant growth and value appreciation in recent times. This acknowledgment reaffirms MultiBank Group's longstanding reputation, extensive experience, and unwavering professionalism in the industry.
With the launch of its cutting-edge mobile application, MultiBank Plus, clients can enjoy lightning-fast access to a wide array of assets, along with advanced trading tools for optimal performance. Offering competitive features such as low spreads, leverage of up to 500:1, and multiple payment methods free from internal charges or commissions, MultiBank Group ensures an unparalleled trading experience for its users.
Serving over 1,000,000 clients globally and maintaining more than 25 offices worldwide, MultiBank Group stands as a premier choice for both novice traders and seasoned investors, providing tailored solutions to meet diverse investment needs.
About MultiBank Group:
MultiBank Group is a leading financial institution with a paid-up capital exceeding US $322 million and a daily average trading volume of $12.1 billion. With over 14 regulatory licenses across the globe, MultiBank Group is widely regarded as one of the most regulated and trusted brokers in the industry. For more information, please visit https://multibankfx.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507590160/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Expereo Appoints Noel Hamill as Chief Marketing Officer6.11.2025 10:00:00 CET | Press release
Expereo, the world-leading managed Network as a Service (NaaS) provider that connects people, places and things anywhere, today announces the appointment of Noel Hamill as its Chief Marketing Officer (CMO), a strategic hire to accelerate the company’s growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106364284/en/ Noel Hamill Hamill joins Expereo with over two decades of marketing leadership experience across global SaaS businesses and consumer brands, including EE and Ladbrokes, PG Forsta and most recently parcelLab, where he served as CMO. In his new role, Hamill will report directly to Ben Elms, CEO, and lead Expereo’s global marketing strategy with a sharp focus on driving growth, expanding market share, and scaling customer acquisition across enterprise and wholesale segments. His appointment underscores Expereo’s commitment to strengthening its brand presence and accelerating adoption of its expereoOne
Energy Transition Solutions Powered by Choice: Trilliant to Share Expertise and Knowledge with Utilities and Smart Cities at Enlit Europe 20256.11.2025 09:00:00 CET | Press release
Product demonstrations and presentations from subject matter experts will highlight key industry insights and the importance of smarter infrastructure to connect systems, empower choice, and unlock performance Trilliant, a leading international provider of solutions for advanced metering infrastructure (AMI), smart grid, smart cities and IIoT, will be an exhibitor, presenter, and Silver Sponsor at Enlit Europe 2025. With product demonstrations on the exhibition floor and compelling presentations from thought leaders, Trilliant will highlight the importance of energy transition solutions, all powered by choice — that are flexible, scalable and interoperable. Taking place November 18- 20, 2025 in Bilboa, Spain, at the Bilbao Exhibition Centre (BEC), Enlit Europe 2025 is an event designed to connect industries, inspire action, and help Europe evolve into a dependable, decarbonised, and digitalised energy system. “As utilities and smart cities across Europe advance their energy transition
Red Hat Introduces Confirmed Sovereign Support for European Union6.11.2025 09:00:00 CET | Press release
Dedicated, EU-citizen-driven support delivers localized operational control and resilience for digital sovereignty Red Hat, the world's leading provider of enterprise open source solutions, today announced Red Hat Confirmed Sovereign Support for the 27 member states of the European Union to address the critical strategic imperative for digital sovereignty in Europe. This new support offering is purpose-built to deliver dedicated EU-citizen-driven technical support from within the EU for Red Hat software subscriptions, providing a new level of verifiable local control over critical IT operations. More and more European business leaders are looking to digital sovereignty as a way to help drive economic differentiation in a global marketplace, as well as insulate operations from geopolitical dynamics and safeguard EU data, technology and operations. At the same time, these leaders want to further cloud infrastructure resiliency and AI innovation goals through strengthened supply chain tra
IFF Benicarló Pioneers On-Site Green Hydrogen Production Facility for Sustainable Fragrance Ingredient Manufacturing6.11.2025 09:00:00 CET | Press release
Local site sets a new benchmark for the fragrance industry IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and biosciences, announced the installation of a nature-based hydrogen production facility at its Scent R&D and fragrance ingredients manufacturing plant in Benicarló, Spain. The site has partnered with Iberdrola, one of the world’s largest producers of renewable energy, to become the first in the fragrance industry to rely on renewable electricity for hydrogenation reactions used in manufacturing key fragrance ingredients. Aligned with the company’s commitment to Do More Good for people and planet, the site’s system can make 100 tons of clean hydrogen annually using renewable energy. It includes a built-in compressor to store hydrogen on-site — reducing the Life Cycle Assessment (LCA) of its products and supporting customers worldwide in achieving their decarbonization goals. This press release features multimedia. View the full release here: https://www
Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe6.11.2025 08:00:00 CET | Press release
Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, a biosimilar to Stelara (ustekinumab)1, in Europe. The terms of the agreement remain confidential. Ustekinumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that prevents abnormal regulation of IL-12 and IL-23 associated with immune-mediated diseases. PYZCHIVA, developed by Samsung Bioepis, was approved as a biosimilar to Stelara (ustekinumab) by the European Commission (EC) in April 2024. PYZCHIVA is currently approved for the treatment of adults and paediatric patients from the age of 6 years and older with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate to severely active Crohn’s disease. “This is a significant milestone for patients living with autoimmune diseases as we are making a step forward in improving access to this important biologic medicine for healthcare systems, pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom